



Barrier or enabler? HTD perspectives on JCA

Moving from an operational to an optimised JCA



James Ryan
Vicechair, EFPIA HTA Working Group
Director, Global HTA Policy, AstraZeneca
16th April 2026



Delivering through joint responsibility and solutions



- ✓ A new process for all
- ✓ Increased volume and challenging timelines
- ✓ Only a handful of HTDs have (partial) JCA experience
- ✓ First time some HTDs are doing any HTA in Europe

Delivering through joint responsibility and solutions



- ✓ Eligibility criteria and associated Secretariat responsiveness
- ✓ Changes with learnings:
 - Start of the procedure
 - Scoping meeting
 - Q&A documents
- ✓ Non duplication of dossier redaction
- ✓ HTDs sharing experiences that they can

Delivering through joint responsibility and solutions



- ✓ Interpretation of guidance
- ✓ Confirmation check vs pre-assessment
- ✓ Type of requests
- ✓ Interpretation of requests
- ✓ Draft JCA report timing
- ✓ Reducing or increasing HTD resource?
- ✓ Member State usage

Delivering through joint responsibility and solutions



- ✓ Pragmatism
- ✓ Continuous learning and adapting
- ✓ Direct and ongoing assessor engagement during a JCA
- ✓ Stakeholder discussions and consultations
- ✓ Bridge with national systems:
 - Process
 - Evidence usage and additions
- ✓ Preparing for rare diseases

Delivering through joint responsibility and solutions



- ✓ Facilitate patient access, improving health outcomes
- ✓ Meaningful national usage
- ✓ Streamline to most impactful data
- ✓ Capacity and timely delivery
- ✓ Deliver efficiency and predictability to **all** stakeholders



Thank you